Neurophysiologic basis of idiopathic diseases

A discovery of a neurophysiologic basis of rheumatism, degenerative and autoimmune diseases and disorders, specifically, fibromyalgia, fibrositis, myofascial pain syndrome, cervicobrachial pain syndrome, palindromic rheumatism, arthropathies, irritable gastrointestinal tract and idiopathic auto-immune soft tissue diseases in a human in whom an injury to, disorder or derangement of the participating tissue or tissues leads to a cascade of events wherein said participating tissues are the tissues of the spine, organs peripheral to said spinal tissues, small, medium and large, unmyelinated and myelinated afferent neurons, preganglionic sympathetic neurons (PESN), postganglionic sympathetic neurons (PSN), interneurons, spinal neurons and immune system and wherein said participating tissues are the participants in the production of said diseases and disorders comprises:

• an injury to said participant;
• a disorder of said participant;
• an injury to said participants;
• a disorder of said participants;
• an activation of said afferent neurons associate with said participant;
• a sensitization of said afferent neurons associate with said participant;
• an activation of said afferent neurons innervating said participant;
• a sensitization of said afferent neurons innervating said participant;
• an activation of said afferent neurons associate with said participants;
• an activation of said afferent neurons innervating said participants;
• a sensitization of said afferent neurons innervating said participants;
• an activation of the PSN by said participants;
• a sensitization of the PSN by said participants;
• an activation of said injured afferent neurons including their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• a sensitization of said injured afferent neurons including their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• an activation of said disordered afferent neurons including their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• a sensitization of said injured afferent neurons including their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• an activation of a second group of afferent neurons by said injured participant;
• an activation of a second group of afferent neurons by said disordered participant;
• a sensitization of a second group of afferent neurons by said injured participants;
• a sensitization of a second group of afferent neurons by said disordered participants;
• an activation of a second group of afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites associate with and by said disordered afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons including the sensitization of their cell bodies, axons, nerve endings and receptors, and dendrites associate with and by said disordered afferent neurons in the peripheral nervous system;
• an activation of a second group of afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites associate with and by said activated afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons including the sensitization of their cell bodies, axons, nerve endings and receptors, and dendrites associate with and by said sensitized afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons associate with and by said activated afferent neurons in the central nervous system leading to the sensitization of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• an activation of a second group of afferent neurons relate to and by said sensitized afferent neurons in the central nervous system leading to the activation of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• an activation of a second group of afferent neurons associate with and by said disordered afferent neurons in the central nervous system leading to the activation of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons associate with and by said injured afferent neurons in the central nervous system leading to the sensitization of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons relate to and by said disordered afferent neurons in the central nervous system leading to the sensitization of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• an activation of PSN relate to said injured participant;
• a sensitization of PSN relate to said disordered participant;
• an activation of PSN relate to said injured participants;
• a sensitization of PSN relate said disordered participants;
• an activation of a second group of afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• a sensitization of a second group of afferent neurons including the sensitization of their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• an activation of PESN by said participants;
• a sensitization of the PESN by said participants;
• an activation of said afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites by injured PSN;
• a sensitization of the afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites by disordered PSN;
• a means for sensitizing the immune system leading to said auto-immune diseases and disorders;
• and
• a means for activating the immune system leading to said auto-immune diseases and disorders.

An elucidation of a neurophysiologic basis of rheumatism, degenerative and autoimmune diseases and disorders, specifically, fibromyalgia, fibrositis, myofascial pain syndrome, trigger point, cervicobrachial pain syndrome, palindromic rheumatism, arthropathies, irritable gastrointestinal tract and idiopathic auto-immune soft tissue diseases in a human in whom an injury to, disorder or derangement of the participating tissue or tissues leads to a cascade of events wherein said participating tissues are the tissues of the spine, organs peripheral to said spinal tissues, small, medium and large, unmyelinated and myelinated afferent neurons, preganglionic sympathetic neurons (PESN), postganglionic sympathetic neurons (PSN), interneurons, spinal neurons and immune system and wherein said participating tissues are the participants in the production of said diseases and disorders comprises:

• an injury to said participant;
• a disorder of said participant;
• an injury to said participants;
• a disorder of said participants;
• an activation of said afferent neurons associate with said participant;
• a sensitization of said afferent neurons associate with said participant;
• an activation of said afferent neurons innervating said participant;
• a sensitization of said afferent neurons innervating said participant;
• an activation of said afferent neurons associate with said participants;
• an activation of said afferent neurons innervating said participants;
• a sensitization of said afferent neurons innervating said participants;
• an activation of the PSN by said participants;
• a sensitization of the PSN by said participants;
• an activation of said injured afferent neurons including their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• a sensitization of said injured afferent neurons including their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• an activation of said disordered afferent neurons including their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• a sensitization of said injured afferent neurons including their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• an activation of a second group of afferent neurons by said injured participant;
• an activation of a second group of afferent neurons by said disordered participant;
• a sensitization of a second group of afferent neurons by said injured participants;
• a sensitization of a second group of afferent neurons by said disordered participants;
• an activation of a second group of afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites associate with and by said disordered afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons including the sensitization of their cell bodies, axons, nerve endings and receptors, and dendrites associate with and by said disordered afferent neurons in the peripheral nervous system;
• an activation of a second group of afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites associate with and by said activated afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons including the sensitization of their cell bodies, axons, nerve endings and receptors, and dendrites associate with and by said sensitized afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons associate with and by said activated afferent neurons in the central nervous system leading to the sensitization of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• an activation of a second group of afferent neurons relate to and by said sensitized afferent neurons in the central nervous system leading to the activation of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• an activation of a second group of afferent neurons associate with and by said disordered afferent neurons in the central nervous system leading to the activation of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons associate with and by said injured afferent neurons in the central nervous system leading to the sensitization of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• a sensitization of a second group of afferent neurons relate to and by said disordered afferent neurons in the central nervous system leading to the sensitization of the peripheral endings and receptors of said second group of afferent neurons in the peripheral nervous system;
• an activation of PSN relate to said injured participant;
• a sensitization of PSN relate to said disordered participant;
• an activation of PSN relate to said injured participants;
• a sensitization of PSN relate said disordered participants;
• an activation of a second group of afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• a sensitization of a second group of afferent neurons including the sensitization of their cell bodies, axons, nerve endings and receptors, and dendrites by PSN;
• an activation of PESN by said participants;
• a sensitization of the PESN by said participants;
• an activation of said afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites by injured PSN;
• a sensitization of the afferent neurons including the activation of their cell bodies, axons, nerve endings and receptors, and dendrites by disordered PSN;
• a means for sensitizing the immune system leading to said auto-immune diseases and disorders;
• and
• a means for activating the immune system leading to said auto-immune diseases and disorders.